AI Medical Technology's Dermalyser Gains CE Mark for Melanoma Detection

AI Medical Technology has received CE mark approval for Dermalyser, a smartphone-based melanoma detection tool, allowing its commercial launch across Europe.

AI Medical Technology has received CE mark approval for its Dermalyser tool, a smartphone-based diagnostic decision support system for melanoma detection, announced in a press release. This approval enables the company to commence commercial operations throughout Europe in 2025.

Dermalyser, designed for use with a dermatoscope, has demonstrated superior performance compared to experienced dermatologists in clinical trials. The tool achieved an AUROC of 0.960, with 95.2% sensitivity and 84.5% specificity, and reached 100% sensitivity for invasive melanomas. These results were validated through a real-world trial conducted at 36 primary care centers across Sweden.

With the CE certification, AI Medical Technology plans to expand its operations in Europe and aims for a U.S. market entry via FDA 510(k) in 2027. The tool's integration into clinical practice is expected to enhance the precision of melanoma detection, offering faster diagnoses and reducing unnecessary surgeries.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish like Life AI Weekly.

Also, consider following us on social media:

Healthcare & Life Sciences AI
AI Brief (X)

More from: Healthcare & Life Sciences

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like